We use a small number of cookies to give you the best experience of our website. If you continue to view the Positive Action site we'll assume that you are happy to receive these cookies. Find out exactly what cookies we use and how to turn them off.

Continue

HIV in the News

This page contains the most recent HIV related news from NAM aidsmap. You can read the full story by clicking on the headlines.

People with HIV are at risk for liver fibrosis and steatosis

Metabolic syndrome, type 2 diabetes and obesity are risk factors for the development of liver fibrosis and steatosis (liver fat accumulation) in people living with HIV, including those who do not have viral hepatitis co-infection, according to research presented at the 9th International AIDS Society Conference on HIV Science (IAS ... full story

Mon, 21 Aug 2017

Switching from efavirenz to raltegravir leads to significant improvements in fatty liver disease in people with HIV

Switching to raltegravir from efavirenz is associated with significant improvements in liver steatosis for HIV-positive people with non-alcoholic fatty liver disease, Spanish investigators report in the online edition of Clinical Infectious Diseases. The benefits of changing therapy were observed in people with and without active hepatitis C virus (HCV) co-infection. ... full story

Thu, 17 Aug 2017

Peripheral artery disease more common in people with HIV with lower CD4 counts

Peripheral artery disease, one of the most common forms of cardiovascular disease, occurs more frequently in people with HIV who have CD4 cell counts below 500, regardless of whether they smoke or have other risk factors for cardiovascular disease, an analysis of the large US Veterans Aging Cohort Study has ... full story

Tue, 15 Aug 2017

PrEP use in US exceeds 100,000 in Gilead pharmacy survey

An estimated 120,000 people in the US have started Truvada for pre-exposure prophylaxis (PrEP) since 2012, according to the latest findings from a survey of retail and mail-order pharmacies by Gilead Sciences. The new numbers, presented at the 9th International AIDS Society Conference on HIV Science (IAS 2017) last month in ... full story

Mon, 14 Aug 2017

Incidence of anal cancer has already peaked among HIV-positive gay men; reductions can be achieved with expanded ART coverage and screening

The incidence of anal cancer among HIV-positive gay men peaked in 2009 and will decline substantially by 2030, even with current levels of antiretroviral therapy (ART) coverage and no cancer-screening programme, Swiss investigators report in AIDS. Further significant reductions would be achieved with 100% treatment coverage and various screening strategies. ... full story

Fri, 11 Aug 2017

Treatment with DAAs reduces the risk of mortality in the first 18 months after the completion of treatment

For the first time, a large study has demonstrated that treatment with direct-acting antivirals (DAAs) significantly reduces mortality rates among people with hepatitis C virus (HCV) monoinfection. The study ? published in Clinical Infectious Diseases ? matched people who received therapy with all-DAA regimens with untreated controls. Mortality rates in ... full story

Thu, 10 Aug 2017

Switch from boosted protease inhibitor to dolutegravir reduces lipids in people with HIV at higher risk of heart disease

Switching from a boosted protease inhibitor to the integrase inhibitor dolutegravir was associated with lipid reductions in people with HIV at higher risk of heart disease, according to results of the NEAT 022 study presented last month at the 9th International AIDS Society Conference on HIV Science (IAS 2017) in ... full story

Wed, 09 Aug 2017

Boosted darunavir plus lamivudine matches three-drug regimen

A combination of darunavir/ritonavir and lamivudine was just as effective as the same combination plus tenofovir, according to 24-week results of the ANDES study presented last month by Professor Pedro Cahn at the 9th IAS Conference on HIV Science in Paris (IAS 2017). Darunavir boosted by ritonavir or cobicistat is recommended ... full story

Tue, 08 Aug 2017

European and US regulators approve AbbVie's new combo for all hepatitis C genotypes

The European Commission and the US Food and Drug Administration (FDA) last week approved AbbVie's new combination pill for people with hepatitis C virus (HCV) genotypes 1 to 6, to be marketed as Maviret in the European Union and as Mavyret in the United States. Maviret is a fixed-dose co-formulation containing ... full story

Mon, 07 Aug 2017

PrEP demand in England is rapidly accelerating ? and most will want to join the trial

A survey of people currently using pre-exposure prophylaxis (PrEP) has found that PrEP use has rapidly accelerated in the last year, with more than half of those surveyed starting since the beginning of 2017. The short survey was conducted by PrEP advocacy sites iwantPrEPnow and PrEPster, with assistance from Public Health England. The study ... full story

Fri, 04 Aug 2017


You can read older stories on the NAM aidsmap news page.